AstraZeneca PLC (NYSE:AZN)

36.79
Delayed Data
As of May 21
 +0.46 / +1.27%
Today’s Change
28.43
Today|||52-Week Range
37.01
+6.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$92.3B

Company Description

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 0382, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Contact Information

AstraZeneca Plc
Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
P:442037495000
Investor Relations:
442076048199

Employees

Shareholders

Mutual fund holders8.17%
Other institutional7.79%
Individual stakeholders--

Top Executives

Pascal SoriotChief Executive Officer & Executive Director
Pam P. ChengExecutive VP-Operations & Information Technology
Marc DunoyerChief Financial Officer & Executive Director
Sean BohenChief Medical Officer & Executive Vice President
Katarina AgeborgChief Compliance Officer